422 related articles for article (PubMed ID: 28465086)
1. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
2. Liposomes assembled from dimeric retinoic acid phospholipid with improved pharmacokinetic properties.
Lu L; Du Y; Ismail M; Ling L; Yao C; Fu Z; Li X
Eur J Pharm Sci; 2018 Jan; 112():186-194. PubMed ID: 29162478
[TBL] [Abstract][Full Text] [Related]
3. Dimeric camptothecin derived phospholipid assembled liposomes with high drug loading for cancer therapy.
Fang S; Hou Y; Ling L; Wang D; Ismail M; Du Y; Zhang Y; Yao C; Li X
Colloids Surf B Biointerfaces; 2018 Jun; 166():235-244. PubMed ID: 29604567
[TBL] [Abstract][Full Text] [Related]
4. Novel dual VES phospholipid self-assembled liposomes with an extremely high drug loading efficiency.
Hou Y; Yao C; Ling L; Du Y; He R; Ismail M; Zhang Y; Fu Z; Li X
Colloids Surf B Biointerfaces; 2017 Aug; 156():29-37. PubMed ID: 28499202
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity.
Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G
Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
[TBL] [Abstract][Full Text] [Related]
7. Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation.
He W; Du Y; Wang T; Wang J; Cheng L; Li X
Int J Pharm; 2021 Sep; 606():120856. PubMed ID: 34229071
[TBL] [Abstract][Full Text] [Related]
8. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
[TBL] [Abstract][Full Text] [Related]
9. Self-assembled liposomes of dual paclitaxel-phospholipid prodrug for anticancer therapy.
Ling L; Du Y; Ismail M; He R; Hou Y; Fu Z; Zhang Y; Yao C; Li X
Int J Pharm; 2017 Jun; 526(1-2):11-22. PubMed ID: 28412448
[TBL] [Abstract][Full Text] [Related]
10. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
11. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
12. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
13. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
Bala V; Rao S; Boyd BJ; Prestidge CA
J Control Release; 2013 Nov; 172(1):48-61. PubMed ID: 23928356
[TBL] [Abstract][Full Text] [Related]
14. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
Fang YP; Chuang CH; Wu YJ; Lin HC; Lu YC
Int J Nanomedicine; 2018; 13():2789-2802. PubMed ID: 29785106
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
17. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
18. Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Wu C; Zhang Y; Yang D; Zhang J; Ma J; Cheng D; Chen J; Deng L
Int J Nanomedicine; 2019; 14():75-85. PubMed ID: 30587986
[TBL] [Abstract][Full Text] [Related]
19. Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy.
Zhang Y; Wang J; Liu C; Xing H; Jiang Y; Li X
J Mater Chem B; 2023 Mar; 11(11):2478-2489. PubMed ID: 36843543
[TBL] [Abstract][Full Text] [Related]
20. Nanoformulation of dual bexarotene-tailed phospholipid conjugate with high drug loading.
He R; Du Y; Ling L; Ismail M; Hou Y; Yao C; Li X
Eur J Pharm Sci; 2017 Mar; 100():197-204. PubMed ID: 28088372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
